Similar content being viewed by others
References
Tatsumi T et al. (2002) Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196: 619–628
Critchley-Thorne RJ et al. (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4: e176
Moschos SJ et al. (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24: 3164–3171
Kirkwood JM et al. (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7–17
Kirkwood JM et al. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB–III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19: 2370–2380
Kirkwood JM et al. (2004) A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10: 1670–1677
Hillner BE (1998) Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma. Eur J Cancer 34 (Suppl 3): S18–S21
Hillner BE et al. (1997) Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 15: 2351–2358
Wheatley K et al. (2007) Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials [abstract #8526]. J Clin Oncol 25 (Suppl)
Gogas H et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709–718
Yurkovetsky ZR et al. (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b. Clin Cancer Res 13: 2422–2428
Tarhini AA et al. (2007) Prognostic significance of serial serum S100 protein levels in high-risk surgically resected melanoma in ECOG phase II trial E2696. In Proceedings of the AACR Annual Meeting 2007: April 14–18; Los Angeles, CA
Stuckert J et al. (2007) Interferon alfa-induced autoimmunity in patients with high-risk melanoma participating in ECOG trial E2696 [abstract #8506]. J Clin Oncol 25 (Suppl)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JM Kirkwood is a speaker for Schering-Plough and receives grant/research support from the company. He also receives grant/research support from Roche. The other authors declared no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Kirkwood, J., Tarhini, A., Moschos, S. et al. Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma. Nat Rev Clin Oncol 5, 2–3 (2008). https://doi.org/10.1038/ncponc1004
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1004
- Springer Nature Limited
This article is cited by
-
Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review
PharmacoEconomics (2017)
-
Primary malignant melanoma of the stomach: report of a case
Surgery Today (2012)
-
Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma
Nature Clinical Practice Oncology (2009)